In the present project we will have access to first-episode patients with schizophrenia (most of them drug-naïve to antipsychotic treatment) and age- and gender-matched healthy volunteers. All individuals are recruited via the Karolinska Schizophrenia Project (KaSP) which is a clinical research program involving collection of detailed phenotypic data, CSF, blood, urine, and brain imaging using MR and PET. The clinical characterization includes the Positive and Negative Syndrome Scale (PANSS) as well as the cognitive test battery MATRICS as well as and prepulse inhibition. From fall 2014, studies aiming at discovering early signs of atherosclerosis (by examining artery stiffness and blood pressure with arteriography) are undertaken and peripheral blood mononuclear cells (PBMCs) and fibroblasts are generated from all subjects for functional studies. All subjects will be monitored and re-examined after 1.5 years and then on a 5-year basis. The project is financed by grants from AZ/TSC, VR, ALF etc (PIs: Sophie Erhardt, Lars Farde, Lena Flyckt). As part of an AstraZeneca KI Translational Science Center grant, we are now proceeding with whole genome sequencing (WGS). Our objective is to perform an extensive mapping of the link rare as well as common variants and, biochemical phenotypes at several levels (blood, CSF, brain) and symptom dimensions. As a first step, we will sequence 80 subjects with whole genome sequencing using IGN with 30x coverage per sample on a Illumina HiSeq 2500 v4, PE 2x125bp.